IBIO iBio, Inc. Common Stock

XNAS 2.05 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

IBIO $2.05 —
Key stats
$2.05
Pre-market $0.73 +2.69%
52-Week Range
$0.69 – $3.82
YTD
+1.49%
Straddle Price
$1.85
P/C Vol Ratio
0.09
Market Cap
$0.0B
Open
$0.73
Day Range
$0.69 – $0.73
Volume
509,284
Prev Close
$0.72
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.09
Cost of Equity (CAPM)10.39%
WACC10.56%
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-28.1%
Book / Price116.5% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-23796.0%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$1.15 (Market Anchor value)
SMA 20 / Bollinger Mid$0.91
Bollinger Width / SMA207647.2% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
70%
20-Day Fair Value
≈ by Nov 25, 2026
$0.72
α +1.2% rank 95%
conviction
67%
40-Day Fair Value
≈ by Dec 24, 2026
$0.72
α +2.4% rank 96%
conviction
74%
60-Day Fair Value
≈ by Jan 22, 2027
$0.72
α +2.4% rank 93%
conviction
70%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $2.89 16% median 3.5× · 3 peers
Peer P/S $0.00 16% median 3.9× · 3 peers
Market Anchor (SMA50) $1.15 68% stability 81% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
23
List Date
2008-08-19
CIK
0001420720
Next Earnings
2026-11-11
EPS Forecast
($0.06) (4 est.)
Headquarters
New York, NY
Homepage
https://www.ibioinc.com

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan31.15%-21.04%10.61%-18.12%24.38%3.96%5.16%
Feb-5.88%-29.39%82.47%13.51%86.26%22.61%28.26%
Mar-14.92%29.56%47.52%227.42%-37.29%-29.37%37.15%
Apr-15.95%-32.28%-36.47%-48.96%-72.89%-13.33%-36.65%
May7.41%-20.96%-35.78%28.65%-25.24%19.50%-4.40%
Jun2.03%16.50%-16.44%-12.45%-7.05%-7.41%-4.14%
Jul-18.42%-12.12%-16.83%1.99%-9.32%-19.99%-12.45%
Aug2.42%19.42%-42.03%-4.37%24.08%-10.56%-1.84%
Sep-17.19%-39.18%3.94%18.09%2.06%-6.35%-6.44%
Oct-25.00%-47.13%-14.68%11.64%94.22%-36.31%*-2.88%
Nov-6.29%-25.24%-38.58%10.11%-30.11%---18.02%
Dec-27.49%-72.23%-54.33%-12.50%75.45%---18.22%
Total-65.89%-96.84%-87.83%116.73%-25.15%-63.15%-37.02%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.91
SMA 50: $1.15
SMA 200: $1.73
Current: $0.71
EMA 12: $0.82
EMA 26: $0.94
MACD: -0.1254 | Signal: -0.0050
BEARISH
ADX (14): 37.05
TREND
+DI: 13.52
−DI: 36.48

Momentum Oscillators

RSI (14): 24.25
OVERSOLD
Stoch %K: 6.22
Stoch %D: 12.17
Williams %R: -94.36

Volume & Volatility

BB Upper: $1.23
BB Lower: $0.59
NEUTRAL
OBV: 324,830,376
Vol SMA 20: 876,883
Vol ROC: 12.56%
ATR: $0.08
True Range: $0.04
HV 20: 81.9%
HV 30: 76.4%
HV 60: 62.3%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary BULLISH (Confidence Level: 6/10)

Key drivers:

  • Recent positive news headlines regarding financial results, corporate updates, and partnerships
  • Strong trend direction in medium-term and long-term momentum indicators
  • Catalysts from earnings and product launches upcoming

Primary risks:

  • High volatility and beta, indicating high risk
  • Overbought conditions in technical indicators
  • Options market pricing a significant move by expiration date

Investment thesis: iBio's recent financial results and partnerships have sparked investor interest, driving the stock higher. The company's proprietary platform and pipeline of novel amylin agonist antibodies demonstrate promising results, supporting a bullish outlook.

Recent news sentiment impact: Positive news headlines from the past 10 articles contribute to a positive sentiment assessment (8/10).

Technical Analysis

Trend Direction:

  • Short-term: NEUTRAL
  • Medium-term: BULLISH
  • Long-term: BULLISH

Support/Resistance Levels:

  • Upper: $1.54 (Bollinger Bands upper band)
  • Middle: $1.40 (SMA 50 and EMA 26)
  • Lower: $1.26 (Bollinger Bands lower band)

Momentum Signals: RSI: NEUTRAL (39.82), MACD: BEARISH (-0.04 / Signal: -0.01 / Histogram: -0.03), Bollinger Bands: NEUTRAL

Volume Analysis:

  • Volume SMA 20: 779269.93
  • On-Balance Volume (OBV): 335337472.00
  • Volume Rate of Change: -64.85% (bearish signal)

News & Sentiment Analysis

Recent Headlines Summary: iBio has reported positive financial results, secured private placements, and announced partnerships in the past year.

Sentiment Assessment: Positive sentiment dominates recent news headlines, contributing to a bullish outlook.

Catalyst Identification: Earnings dates, product launches, and regulatory approvals remain key catalysts for future price movements.

Market Narrative: The market narrative aligns with technical signals, indicating a bullish trend.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta = 2.17)

Volatility Regime: Current volatility is higher than historical levels

Options Market Signals: IV Rank: Low (0.0%), Options volume flow indicates bull call spread activity

Downside Protection: Support levels at $1.26 and $1.40 may provide some protection against potential declines.

Market Context & Positioning

Sector Performance: iBio's sector performance is mixed, but the biotech industry shows promise.

Institutional Activity: Volume patterns suggest institutional interest in the stock.

Correlation Analysis: The stock moves independently of the market (R-squared = 0.25).

Relative Valuation: iBio's relative valuation is fair, considering its pipeline and recent financial results.

Key Levels & Action Items

Critical Price Levels:

  • Support: $1.26 and $1.40
  • Resistance: $1.54

Breakout/Breakdown Levels:

  • Breakout above $1.54 may trigger a bullish momentum surge
  • Breakdown below $1.26 could lead to a bearish trend continuation

Time-Sensitive Catalysts: Earnings dates, product launches, and regulatory approvals remain key catalysts for future price movements.

Risk Management: Stop-loss levels at $1.20 and position sizing considerations are essential in managing risk.

By analyzing the technical indicators, news sentiment, and risk metrics, we conclude that iBio's stock is BULLISH with a confidence level of 6/10. The company's recent financial results, partnerships, and pipeline developments have sparked investor interest, driving the stock higher. However, high volatility, beta, and options market signals indicate a high-risk investment opportunity.

Generated
News
All IBIO news →
Earnings History
3 of 5 under expected move
Avg Expected Move
28.07%
Avg Actual Move
13.82%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-16 unknown 24.79% 12.02% 0.48x Within
2021-05-17 Pre-Market 21.48% 7.48% 0.35x Within
2022-05-12 After-Close 1.33% 7.00% 5.26x Exceeded
2022-09-27 unknown 1.07% 32.28% 30.17x Exceeded
2023-08-07 unknown 91.67% 10.30% 0.11x Within

Earnings calendar: this week’s reports with expected vs actual moves →

IBIO Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $1.85
7-DTE Move: $1.85
Days to Exp: — (2024-06-21)

Options Flow

Call Volume: 35
Put Volume: 3
P/C Volume: 0.086
BULLISH
Call OI: 4,878
Put OI: 10
P/C OI: 0.002
Total OI: 4,888

ATM Options Pricing

ATM Call: $0.03
ATM Put: $1.82
Call %: 1.2%
Put %: 89.0%

Chain Summary

Chain Volume: 38
Chain OI: 4,888
Last Updated: 6/21/2024
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Jun 10 · No data
30 DTE / 10d —
— pts EXTREME
as of Jun 10 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.85Jun 21
Beta Analysis

Risk Metrics

Beta: 2.2911
Alpha: -31.15%
Correlation: 0.2762
R-Squared: 7.6%
Stock Volatility: 105.7%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own IBIO
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$2.9M
0.00%
#2373 of 3716+6.6%13F
Citadel Hedge fund
Ken Griffin
$2.4M
0.00%
#2729 of 6285+44.7%13F
Renaissance Technologies Hedge fund
Jim Simons
$355K
0.00%
#2722 of 3138new13F
Rockefeller Capital Management Family office
Rockefeller family
$0K
0.00%
#4721 of 4729new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

IBIO Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 104,060,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

58 filers35,623,306 shares$62.50M value34.23% of float
# Filer Shares Value % of Total % of Float Period
1 Affinity Asset Advisors, LLC 4,007,881 $7.01M 11.22% 3.85% 2026-06-30
2 Cormorant Asset Management, LP 3,570,000 $6.25M 10.00% 3.43% 2026-06-30
3 SILVERARC CAPITAL MANAGEMENT, LLC 3,520,490 $6.16M 9.86% 3.38% 2026-06-30
4 Vestal Point Capital, LP 2,600,000 $4.55M 7.28% 2.50% 2026-06-30
5 Vanguard Capital Management LLC 2,098,151 $3.67M 5.87% 2.02% 2026-06-30
6 Frazier Life Sciences Management, L.P. 1,953,467 $3.42M 5.47% 1.88% 2026-06-30
7 Ensign Peak Advisors, Inc 1,832,457 $3.21M 5.13% 1.76% 2026-06-30
8 Woodline Partners LP 1,776,547 $3.11M 4.97% 1.71% 2026-06-30
9 Millennium Management LLC Custodian 1,651,473 $2.89M 4.62% 1.59% 2026-06-30
10 Citadel Advisors LLC Custodian 1,384,029 $2.42M 3.88% 1.33% 2026-06-30
11 Balyasny Asset Management L.P. 1,170,893 $2.05M 3.28% 1.13% 2026-06-30
12 Bank of America Corp Custodian 1,121,492 $1.96M 3.14% 1.08% 2026-06-30
13 Vanguard Group Inc Custodian 883,149 $1.70M 2.73% 0.85% 2025-12-31
14 Ikarian Capital, LLC 957,062 $1.67M 2.68% 0.92% 2026-06-30
15 Sio Capital Management, LLC 904,268 $1.58M 2.53% 0.87% 2026-06-30
16 Marshall Wace, LLP Custodian 904,132 $1.58M 2.53% 0.87% 2026-06-30
17 Geode Capital Management, LLC Custodian 500,816 $876.65K 1.40% 0.48% 2026-06-30
18 Walleye Capital LLC 500,375 $875.66K 1.40% 0.48% 2026-06-30
19 Squarepoint Ops LLC 498,872 $873.03K 1.40% 0.48% 2026-06-30
20 NOESIS CAPITAL MANGEMENT CORP 405,000 $708.75K 1.13% 0.39% 2026-06-30
21 Two Sigma Investments, LP Custodian 400,667 $701.17K 1.12% 0.39% 2026-06-30
22 Ally Bridge Group (NY) LLC 390,147 $682.76K 1.09% 0.37% 2026-06-30
23 ADAR1 Capital Management, LLC 375,531 $657.18K 1.05% 0.36% 2026-06-30
24 Verdad Advisers, LP 298,927 $523.12K 0.84% 0.29% 2026-06-30
25 Vanguard Fiduciary Trust Co 286,875 $502.03K 0.80% 0.28% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

IBIO Insider Trading (Form 4)

Latest: 2026-10-15
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-15 Antonio Bernardino Guimaraes Parada Director Grant (A) +38,000 opt — EDGAR
2026-10-15 David Arkowitz Director Grant (A) +38,000 opt — EDGAR
2026-10-15 William D Clark Director Grant (A) +38,000 opt — EDGAR
2026-10-15 Elizabeth Stoner Director Grant (A) +38,000 opt — EDGAR
2026-10-15 Alexandra Kropotova Director Grant (A) +38,000 opt — EDGAR
2026-10-15 Gary Sender Director Grant (A) +38,000 opt — EDGAR
2026-08-04 Molly Carr Chief Medical Officer Grant (A) +430,000 opt — EDGAR
2026-05-19 Elizabeth Stoner Director Grant (A) +60,000 opt — EDGAR
2026-03-27 Marc Banjak Chief Legal Officer Buy (P) +13,934 $1.65 $23.1K EDGAR
2026-03-23 Felipe Duran Chief Financial Officer Buy (P) +24,835 $2.02 $50.1K EDGAR
2026-03-23 Martin Brenner See Remarks Buy (P) +12,336 $2.02 $24.9K EDGAR
2026-01-30 Martin Brenner See Remarks Grant (A) +479,000 opt — EDGAR
2026-01-30 Marc Banjak Chief Legal Officer Grant (A) +146,000 opt — EDGAR
2026-01-30 Felipe Duran Chief Financial Officer Grant (A) +179,000 opt — EDGAR
2025-11-24 Gary Sender Director Grant (A) +13,500 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

IBIO Insider Holdings

7 insiders · @ $0.71
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Antonio Bernardino Guimaraes Parada Director 183,823 $130.0K $500.0K 4 2026-10-15
2 Felipe Duran Chief Financial Officer 35,974 $25.4K $75.1K 9 2026-03-23
3 Martin Brenner See Remarks 30,652 $21.7K -$15.8K 25 2026-03-23
4 Marc Banjak Chief Legal Officer 25,000 $17.7K $48.1K 5 2026-03-27
5 David Arkowitz Director 18,382 $13.0K $50.0K 4 2026-10-15
6 Gary Sender Director 9,191 $6.5K $25.0K 6 2026-10-15
7 William D Clark Director 1,838 $1.3K $5.0K 6 2026-10-15
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

IBIO Board & Officers

As of SEC filings through Oct 15, 2026

Directors 7

Officers 4

  • Martin Brenner · Chief Executive Officer and Chief Scientific Officer · listed since Jun 2023
  • Felipe Duran · Chief Financial Officer · listed since Apr 2023
  • Marc Banjak · Chief Legal Officer · since Aug 14, 2024
  • Molly Carr · Chief Medical Officer · since Jul 31, 2026
Changes in the last 10 years (33)
Jul 31, 2026Molly Carr became Chief Medical Officer
May 7, 2026The company announced the departure of Evert B. Schimmelpennink from the board in an SEC filing
May 7, 2026Elizabeth Stoner became a director
Jan 13, 2025Martin Brenner first listed as a director in an SEC filing
Nov 21, 2024David Arkowitz became a director
Nov 21, 2024Antonio Bernardino Guimaraes Parada became a director
Aug 14, 2024Marc Banjak became Chief Legal Officer
Jun 27, 2023Martin Brenner listed as Chief Executive Officer and Chief Scientific Officer (previously Interim Chief Executive Officer and Chief Scientific Officer) in SEC filings
Apr 3, 2023Felipe Duran listed as Chief Financial Officer (previously Interim CFO) in SEC filings
Feb 23, 2023Martin Brenner listed as Interim Chief Executive Officer and Chief Scientific Officer (previously Chief Scientific Officer) in SEC filings
Feb 13, 2023Felipe Duran became Interim CFO
Jan 11, 2023The company announced the departure of Robert Matthew Lutz as Chief Financial & Business Officer and Principal Accounting Officer in an SEC filing
Dec 1, 2022The company announced the departure of Thomas Francis 3rd Isett from the board in an SEC filing
Dec 1, 2022The company announced the departure of Thomas Francis 3rd Isett as CEO and Executive Chairman in an SEC filing
Apr 28, 2022The company announced the departure of Randy Joe Maddux as Chief Operating Officer in an SEC filing
Dec 13, 2021John D McKey Jr reported in an SEC filing no longer being a director
Aug 23, 2021William D Clark became a director
Jun 7, 2021Evert B. Schimmelpennink became a director
Mar 4, 2021Robert Matthew Lutz became Chief Financial & Business Officer and Principal Accounting Officer
Jan 18, 2021Martin Brenner became Chief Scientific Officer
Not reported recently (11)
  • Linda Washington Armstrong · Last reported as a director in an SEC filing dated Oct 26, 2022
  • HILL (Ret) JAMES T. GENERAL · Last reported as a director in an SEC filing dated Dec 13, 2021
  • Glenn Chang · Last reported as a director in an SEC filing dated Dec 13, 2021
  • Robert Kay · Last reported as a director in an SEC filing dated Oct 28, 2020
  • John Delta · Last reported as Principal Accounting Officer in an SEC filing dated Oct 5, 2020
  • Robert L Erwin · Last reported as President in an SEC filing dated Jun 8, 2020
  • James P. Mullaney · Last reported as Chief Financial Officer in an SEC filing dated May 29, 2020
  • Philip K. Russell · Last reported as a director in an SEC filing dated Aug 14, 2019
  • Seymour Flug · Last reported as a director in an SEC filing dated May 31, 2019
  • Ryan E Terence · Last reported as Chief Scientific Officer in an SEC filing dated May 13, 2019
  • Mark A Giannone · Last reported as Chief Financial Officer in an SEC filing dated Apr 5, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold IBIO
3 shown · $2.52M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $1.7M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $686,844 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $103,762 $1.2B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.21
TTM Revenue
$100.00K
TTM Net Income
$-24.06M
TTM Op. Cash Flow
$-23.22M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '262026-06-30$0.00$-10.58M$-0.04$-6.21M
Q3 '262026-03-31—$-7.76M$-0.06$-6.10M
Q2 '262025-12-31———$-5.24M
Q1 '262025-09-30$100.00K$-5.72M$-0.11$-5.67M
Q4 '252025-06-30$200.00K$-5.16M$-0.36$-4.62M
Q3 '252025-03-31—$-4.86M$-0.49$-3.10M
Q2 '252024-12-31$200.00K$-4.36M$-0.48$-3.87M
Q1 '252024-09-30—$-3.99M$-0.46$-3.71M
Q4 '242024-06-30$175.00K$-7.78M$1.12$-4.85M
Q3 '242024-03-31—$-3.17M$-0.85$-3.65M
Q2 '242023-12-31—$-8.21M$-4.42$-4.71M
Q1 '242023-09-30$50.00K$-5.75M$-4.80$-5.34M
Q4 2026 • period ending 2026-06-30 • filed 2026-08-28
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.86
P/S
735.70
EV/EBITDA
—
EV/Sales
171.75
ROE
-28.1%
ROA
-24.3%
Div Yield
0.00%
FCF Yield
-31.56%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$73.57M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.20M
SI % of Float
7.60%
Days to Cover
6.17
Short Vol Ratio
66.0%
Free Float
55.28M
Float %
86.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-01